Graduate Institute of Biomedical Materials & Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
Research and Marketing Department, MTAMTech Corporation, Taipei, Taiwan.
J Biomed Mater Res B Appl Biomater. 2024 Jan;112(1):e35348. doi: 10.1002/jbm.b.35348.
Encapsulated cell therapy (ECT) shows significant potential for treating neurodegenerative disorders including Alzheimer's and Parkinson's, which currently lack curative medicines and must be managed symptomatically. This novel technique encapsulates functional cells with a semi-permeable membrane, providing protection while enabling critical nutrients and therapeutic substances to pass through. Traditional ECT procedures, on the other hand, pose difficulties in terms of cell survival and retrieval. We introduce the Microtube Array Membrane (MTAM), a revolutionary technology that solves these constraints, in this comprehensive overview. Microtube Array Membrane has distinct microstructures that improve encapsulated cells' long-term viability by combining the advantages of macro and micron scales. Importantly, the MTAM platform improves biosafety by allowing the entire encapsulated unit to be retrieved in the event of an adverse reaction. Our findings show that MTAM-based ECT has a great potential in a variety of illness situations. For cancer treatment, hybridoma cells secreting anti-CEACAM 6 antibodies inhibit triple-negative breast cancer cell lines for an extended period of time. In animal brain models of Alzheimer's disease, hybridoma cells secreting anti-pTau antibodies successfully reduce pTau buildup, accompanied by improvements in memory performance. In mouse models, MTAM-encapsulated primary cardiac mesenchymal stem cells dramatically improve overall survival and heart function. These findings illustrate the efficacy and adaptability of MTAM-based ECT in addressing major issues such as immunological isolation, cell viability, and patient safety. We provide new possibilities for the treatment of neurodegenerative illnesses and other conditions by combining the potential of ECT with MTAM. Continued research and development in this subject has a lot of promise for developing cell therapy and giving hope to people suffering from chronic diseases.
封装细胞疗法 (ECT) 在治疗神经退行性疾病方面具有巨大的潜力,包括阿尔茨海默病和帕金森病,这些疾病目前缺乏治愈药物,只能对症治疗。这项新技术将功能性细胞封装在半透膜中,在提供保护的同时,允许关键营养物质和治疗物质通过。然而,传统的 ECT 程序在细胞存活和回收方面存在困难。在这篇全面综述中,我们介绍了 Microtube Array Membrane(MTAM),这是一种解决这些限制的革命性技术。MTAM 具有独特的微结构,通过结合宏观和微观尺度的优势,提高了封装细胞的长期存活率。重要的是,MTAM 平台通过允许在发生不良反应时回收整个封装单元,提高了生物安全性。我们的研究结果表明,基于 MTAM 的 ECT 在各种疾病情况下都具有巨大的潜力。在癌症治疗方面,分泌抗-CEACAM 6 抗体的杂交瘤细胞能够长时间抑制三阴性乳腺癌细胞系。在阿尔茨海默病动物脑模型中,分泌抗-pTau 抗体的杂交瘤细胞成功减少了 pTau 的积累,同时改善了记忆性能。在小鼠模型中,MTAM 封装的原代心脏间充质干细胞显著提高了整体存活率和心脏功能。这些发现说明了基于 MTAM 的 ECT 在解决免疫隔离、细胞活力和患者安全等重大问题方面的疗效和适应性。通过将 ECT 的潜力与 MTAM 相结合,我们为治疗神经退行性疾病和其他疾病提供了新的可能性。在这个领域继续进行研究和开发,为开发细胞疗法提供了很大的希望,也为患有慢性疾病的人带来了希望。